Format

Send to

Choose Destination
Haematologica. 2016 Apr;101(4):396-406. doi: 10.3324/haematol.2015.129189.

Treatment of relapsed and refractory multiple myeloma.

Author information

1
Erasmus MC Cancer Institute, Department of Hematology, Rm Na824, Rotterdam, the Netherlands p.sonneveld@erasmusmc.nl.
2
Erasmus MC Cancer Institute, Department of Hematology, Rm Na824, Rotterdam, the Netherlands.

Abstract

The approach to the patient with relapsed or relapsed/refractory multiple myeloma (RRMM) requires a careful evaluation of the results of previous treatments, the toxicities associated with them and an assessment of prognostic factors. Since the majority of patients will have received prior therapy with drug combinations including a proteasome inhibitor and/or an immunomodulatory drug (IMiD), it is the physician's task to choose the right moment for the start of therapy and define with the patient which goals need to be achieved. The choice of regimen is usually based on prior responsiveness, drugs already received, prior adverse effects, the condition of the patient and expected effectiveness and tolerability. Many double and triple drug combinations are available. In addition, promising new drugs like pomalidomide, carfilzomib and monoclonal antibodies are, or will be, available shortly, while other options can be tried in clinical studies. Finally, supportive care and palliative options need to be considered in some patients. It is becoming increasingly more important to consider the therapeutic options for the whole duration of the disease rather than take a step by step approach, and to develop a systematic approach for each individual patient.

PMID:
27033237
PMCID:
PMC5004403
DOI:
10.3324/haematol.2015.129189
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center